Special Issue

Drug Delivery in Ophthalmology

Message from the Guest Editor

The eye is an interesting organ for drug delivery development owing to its accessibility and monitoring feasibility to record physiological activity versus morphological features. The progress in our comprehension of disease mechanisms has made it possible to identify multiple targets to develop new treatments for inherited retinal dystrophies and glaucoma. However, small molecules often have a very short half-life in the eye, rendering repetitive treatments problematic. Concerning genetic diseases, gene transfer has brought great success with the proof-ofconcept that a gene augmentation strategy can restore some visual functions over the course of months or even years. Many clinical trials are ongoing, but few data are available about the patients or from a methodological point of view. This Special Issue aims to present different reviews on the successes, hurdles, and potential solutions with drug delivery into the eye using small molecules such as nanodrugs, nonviral and viral drug delivery, as well as antisense oligonucleotides, and to help each researcher choose the adequate tool for the disease which they aim to target.

Guest Editor

Prof. Dr. Yvan Arseniievic

Unit of Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Hôpital Ophtalmique Jules-Gonin, Fondation Asile des aveugles, 1004 Lausanne, Switzerland

Deadline for manuscript submissions

closed (10 November 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/93022

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

